Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393991 · ClinicalTrials.gov registry record · Phase 3
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma
A Phase 3 study, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 475
- Enrollment target
NCT00393991: Completed Phase 3 study, sponsored by SkyePharma.
NCT00393991 is a Phase 3 study that has completed, run by SkyePharma. The registered enrollment target is 475 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393991, a Phase 3 study, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 475 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with mild to moderate asthma.
Interventions
- DRUG Placebo
- DRUG Formoterol fumarate 10
- DRUG Fluticasone propionate 100
- DRUG Fluticasone propionate/formoterol fumarate 100/10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393991
The ClinicalTrials.gov registry entry for NCT00393991 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SkyePharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00393991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00393991 about?
NCT00393991 is a clinical study titled "Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma". The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with mild to moderate asthma.
What is the current status of trial NCT00393991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 475 participants. The study started on 2006-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00393991?
The interventions under investigation include: Placebo (DRUG), Formoterol fumarate 10 (DRUG), Fluticasone propionate 100 (DRUG), Fluticasone propionate/formoterol fumarate 100/10 (DRUG).
Who is sponsoring clinical trial NCT00393991?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.